Retatrutide
Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist on the GLP-1, GIP, and glucagon receptors.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1379072909 under CC BY-SA 4.0; modifications have been made.